Abstract
Article AbstractLetter to the Editor Sir: Clozapine continues to be the gold standard for patientswith treatment-refractory schizophrenia.1 However, when patientswho have responded to clozapine need to have clozapinetreatment discontinued due to a serious adverse event, such asglucose abnormalities, clinicians are often confronted with difficult choices regarding a suitable substitute treatment.We present a patient who developed acute ketoacidosis while on clozapine treatment and who developed severe agitationand psychotic decompensation with subsequent aripiprazole treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
